INDP Indaptus Therapeutics, Inc.

Nasdaq indaptusrx.com


$ 2.55 $ -0.14 (-5.22 %)    

Friday, 07-Nov-2025 15:59:51 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 2.54
$ 2.66
$ 2.43 x 1
$ 2.81 x 100
$ 2.45 - $ 2.68
$ 2.22 - $ 47.60
27,138
na
2.81M
$ 1.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of t...

Core News & Articles

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The m...

 indaptus-reports-partial-response-from-decoy20-monotherapy-in-urothelial-cancer-combo-with-pd-1-inhibitor-shows-favorable-safety

Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastasesDecoy20 combination with PD-...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION